Diversify Advisory Services LLC Purchases Shares of 15,872 TransMedics Group, Inc. $TMDX

Key Points

• Diversify Advisory Services acquired 15,872 TransMedics Group shares worth approximately $1.18 million, while institutional investors collectively own 99.67% of the stock.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings of $0.44 per share missed consensus by $0.06.
• Analyst sentiment is mixed, with an overall “Hold” rating and an average price target of $124.18; shares opened at $93.97 after recent target-price reductions from several firms.

Diversify Advisory Services LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 15,872 shares of the company's stock, valued at approximately $1,179,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its holdings in shares of TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company's stock worth $117,506,000 after buying an additional 322,353 shares in the last quarter. Two Sigma Investments LP increased its stake in shares of TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company's stock valued at $71,291,000 after acquiring an additional 223,409 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of TransMedics Group by 100.5% in the 4th quarter. Wellington Management Group LLP now owns 433,321 shares of the company's stock valued at $52,713,000 after acquiring an additional 217,180 shares in the last quarter. Deutsche Bank AG acquired a new position in shares of TransMedics Group during the 2nd quarter valued at $14,415,000. Finally, Bank of New York Mellon Corp bought a new position in TransMedics Group during the second quarter worth $12,869,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares of the company's stock, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company's stock.

TransMedics Group Stock Up 3.6%

TransMedics Group stock opened at $93.97 on Thursday. The firm has a market capitalization of $3.25 billion, a price-to-earnings ratio of 24.16 and a beta of 1.90. The firm's fifty day moving average price is $76.71 and its two-hundred day moving average price is $95.63. TransMedics Group, Inc. has a 1-year low of $60.10 and a 1-year high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same period in the previous year, the firm earned $0.92 earnings per share. The company's revenue was up 20.7% on a year-over-year basis. On average, equities research analysts predict that TransMedics Group, Inc. will post 1.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TMDX. Weiss Ratings cut shares of TransMedics Group from a "hold (c)" rating to a "hold (c-)" rating in a report on Tuesday, July 28th. UBS Group dropped their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a report on Wednesday, August 5th. Canaccord Genuity Group reissued a "buy" rating and set a $124.00 price objective on shares of TransMedics Group in a research report on Tuesday, June 30th. Needham & Company LLC reduced their target price on TransMedics Group from $142.00 to $106.00 and set a "buy" rating for the company in a research note on Monday, August 3rd. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $124.18.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source